{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?date=2021-02-05&min-answer.questionFirstAnswered.=2019-07-05T11%3A23%3A04.133Z&tablingMemberConstituency=Norwich+South&max-answer.dateOfAnswer=2021-02-15", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?date=2021-02-05&min-answer.questionFirstAnswered.=2019-07-05T11%3A23%3A04.133Z&tablingMemberConstituency=Norwich+South&max-answer.dateOfAnswer=2021-02-15", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?date=2021-02-05&min-answer.questionFirstAnswered.=2019-07-05T11%3A23%3A04.133Z&tablingMemberConstituency=Norwich+South&_metadata=all&max-answer.dateOfAnswer=2021-02-15", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?date=2021-02-05&_page=0&min-answer.questionFirstAnswered.=2019-07-05T11%3A23%3A04.133Z&tablingMemberConstituency=Norwich+South&max-answer.dateOfAnswer=2021-02-15", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?date=2021-02-05&min-answer.questionFirstAnswered.=2019-07-05T11%3A23%3A04.133Z&tablingMemberConstituency=Norwich+South&max-answer.dateOfAnswer=2021-02-15", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?date=2021-02-05&min-answer.questionFirstAnswered.=2019-07-05T11%3A23%3A04.133Z&tablingMemberConstituency=Norwich+South&max-answer.dateOfAnswer=2021-02-15", "items" : [{"_about" : "http://data.parliament.uk/resources/1284395", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1284395/answer", "answerText" : {"_value" : "<p>The Government has made no such assessment and does not consider waiving intellectual property rights to be an appropriate course of action to boost the manufacturing of safe, effective and quality vaccines. The existing intellectual property framework has mobilised research and development to deliver a host of new medicines and technologies, to detect, treat and defend against COVID-19.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
        }
        , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
        , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
        , "dateOfAnswer" : {"_value" : "2021-02-15", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-02-15T17:26:12.45Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2021-02-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "TRIPS Agreement"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether his Department has undertaken an impact assessment on public health implications for the UK in the event that the proposed World Trade Organisation TRIPS Waiver is not approved.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4500", "label" : {"_value" : "Biography information for Clive Lewis"}
      }
      , "tablingMemberConstituency" : {"_value" : "Norwich South"}
      , "tablingMemberPrinted" : [{"_value" : "Clive Lewis"}
      ], "uin" : "149799"}
    , {"_about" : "http://data.parliament.uk/resources/1284396", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1284396/answer", "answerText" : {"_value" : "<p>The UK Government does not consider waiving IP rights to be an appropriate course of action to boost the manufacturing of safe, effective and quality vaccines.<\/p><p> <\/p><p>The existing intellectual property framework has mobilised research and development to deliver a host of new medicines and technologies, to detect, treat and defend against COVID-19. The incentives and access mechanisms provided by the IP framework have been integral to this success, without which we would not have seen the impressive surge of R&amp;D and the unprecedented scaling up of production.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4372", "label" : {"_value" : "Biography information for Amanda Solloway"}
        }
        , "answeringMemberConstituency" : {"_value" : "Derby North"}
        , "answeringMemberPrinted" : {"_value" : "Amanda Solloway"}
        , "dateOfAnswer" : {"_value" : "2021-02-15", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-02-15T17:51:37.377Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "201"}
      , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "date" : {"_value" : "2021-02-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Intellectual Property"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, whether his Department has undertaken an impact assessment on potential economic costs for the UK in the event that the proposed World Trade Organisation TRIPS Waiver is not approved.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4500", "label" : {"_value" : "Biography information for Clive Lewis"}
      }
      , "tablingMemberConstituency" : {"_value" : "Norwich South"}
      , "tablingMemberPrinted" : [{"_value" : "Clive Lewis"}
      ], "uin" : "149800"}
    , {"_about" : "http://data.parliament.uk/resources/1284397", "AnsweringBody" : [{"_value" : "Foreign, Commonwealth and Development Office"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1284397/answer", "answerText" : {"_value" : "<p>The UK is committed to rapid equitable access to safe and effective vaccines, and is playing a leading role in financing the global effort, and identifying solutions that ensure affordable access for all.<\/p><p>The UK Government does not consider waiving intellectual property (IP) rights to be an appropriate course of action in boosting the manufacturing of safe, effective, and quality vaccines. The existing intellectual property framework has mobilised research and development to deliver a host of new medicines and technologies to detect, treat, and defend against COVID-19. The incentives and access mechanisms provided by the IP framework have been integral to this success, without which we would not have seen the impressive surge of research and development, and the unprecedented scaling up of production.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4358", "label" : {"_value" : "Biography information for Wendy Morton"}
        }
        , "answeringMemberConstituency" : {"_value" : "Aldridge-Brownhills"}
        , "answeringMemberPrinted" : {"_value" : "Wendy Morton"}
        , "dateOfAnswer" : {"_value" : "2021-02-15", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-02-15T09:33:49.997Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "208"}
      , "answeringDeptShortName" : {"_value" : "Foreign, Commonwealth and Development Office"}
      , "answeringDeptSortName" : {"_value" : "Foreign, Commonwealth and Development Office"}
      , "date" : {"_value" : "2021-02-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what assessment the Government has made of the effect on global equality of access to the covid-19 vaccines in the event that the proposed WTO TRIPS Waiver is not adopted.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4500", "label" : {"_value" : "Biography information for Clive Lewis"}
      }
      , "tablingMemberConstituency" : {"_value" : "Norwich South"}
      , "tablingMemberPrinted" : [{"_value" : "Clive Lewis"}
      ], "uin" : "149801"}
    , {"_about" : "http://data.parliament.uk/resources/1284399", "AnsweringBody" : [{"_value" : "Department for International Trade"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1284399/answer", "answerText" : {"_value" : "<p>The UK has engaged regularly in debates at the World Trade Organisation (WTO) TRIPS Council and other international institutions to promote affordable and equitable global access to COVID-19 vaccines, including in developing countries. We respect the informal format of WTO discussions and do not publish proceedings from those meetings. However, at the informal TRIPS Council on 4 February 2021, the UK sought to further understand the parameters of the proposed waiver and asked for clarifications from the waiver\u2019s proponents. This remains consistent with the Government\u2019s approach to encourage evidence-based discussions between WTO Members to find solutions to present issues within the multilateral intellectual property framework.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1526", "label" : {"_value" : "Biography information for Greg Hands"}
        }
        , "answeringMemberConstituency" : {"_value" : "Chelsea and Fulham"}
        , "answeringMemberPrinted" : {"_value" : "Greg Hands"}
        , "dateOfAnswer" : {"_value" : "2021-02-15", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-02-15T11:53:53.13Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "202"}
      , "answeringDeptShortName" : {"_value" : "International Trade"}
      , "answeringDeptSortName" : {"_value" : "International Trade"}
      , "date" : {"_value" : "2021-02-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "TRIPS Agreement"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for International Trade, if she will publish statements made by the Government related to the proposed TRIPS Waiver at the World Trade Organisation TRIPS Council Meeting on 4 February 2021.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4500", "label" : {"_value" : "Biography information for Clive Lewis"}
      }
      , "tablingMemberConstituency" : {"_value" : "Norwich South"}
      , "tablingMemberPrinted" : [{"_value" : "Clive Lewis"}
      ], "uin" : "149802"}
    , {"_about" : "http://data.parliament.uk/resources/1284400", "AnsweringBody" : [{"_value" : "Foreign, Commonwealth and Development Office"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1284400/answer", "answerText" : {"_value" : "<p>The UK will champion rapid equitable access to safe and effective vaccines throughout our G7 Presidency.<\/p><p>Since the World Health Organisation (WHO) provided initial details on the COVID-19 technology access pool (C-TAP) in October, the UK has led the way in bringing industry and the research community to the table. During our G7 presidency, we will continue this work with stakeholders and the WHO as it establishes the governance structures and refines the operating model for C-TAP.<\/p><p>The FCDO is working closely with key development partners in vaccines, such as the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccines Alliance, WHO and the United Nations International Children's Emergency Fund (UNICEF), along with development finance institutions and the private sector to catalyse investments for vaccine manufacturing in Africa.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4358", "label" : {"_value" : "Biography information for Wendy Morton"}
        }
        , "answeringMemberConstituency" : {"_value" : "Aldridge-Brownhills"}
        , "answeringMemberPrinted" : {"_value" : "Wendy Morton"}
        , "dateOfAnswer" : {"_value" : "2021-02-12", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-02-12T11:48:39.703Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "208"}
      , "answeringDeptShortName" : {"_value" : "Foreign, Commonwealth and Development Office"}
      , "answeringDeptSortName" : {"_value" : "Foreign, Commonwealth and Development Office"}
      , "date" : {"_value" : "2021-02-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, if the Government will take steps to use its Presidency of the G7 to propose support for (a) the WHO COVID-19 Technology Access Pool and (b) increasing Official Development Assistance funding to scale-up vaccine manufacturing capacity in low and middle income countries.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4500", "label" : {"_value" : "Biography information for Clive Lewis"}
      }
      , "tablingMemberConstituency" : {"_value" : "Norwich South"}
      , "tablingMemberPrinted" : [{"_value" : "Clive Lewis"}
      ], "uin" : "149803"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 5, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}